Harold Brubaker

1 week ago | inquirer.com | Harold Brubaker

ChristianaCare won Tuesday’s bankruptcy auction for five of Crozer Health’s outpatient locations, the nonprofit health system confirmed Wednesday. Multiple sources said ChristianaCare’s winning bid was $50 million, topping Main Line Health. The auction win by Delaware’s largest health system allows ChristianaCare to step into Crozer’s leases at buildings in Broomall, Glen Mills, Media, and Havertown. Crozer has two locations in Glen Mills.

1 week ago | inquirer.com | Harold Brubaker

Virtua Health, South Jersey’s largest health system, celebrated the start of construction of a $500 million expansion and renovation of Our Lady of Lourdes in Camden, part of a Catholic health system Virtua acquired in 2019. A six-story patient pavilion, named in honor of philanthropist Marvin Samson, will have 78 private patient rooms, 10 operating suites, 4 cardiac catheterization labs, and other facilities, Virtua said Wednesday. The existing hospital has 340 beds.

1 week ago | inquirer.com | Harold Brubaker

Thomas Jefferson University, which owns Jefferson Health, extended CEO Joseph G. Cacchione’s contract through 2029, the Philadelphia nonprofit announced Wednesday. Cacchione’s current contract was set to expire at the end of 2027. Cacchione, 63, came to Jefferson in September 2022 from Ascension, a large Catholic healthcare system, where he had been executive vice president for clinical and network services. Cacchione is a cardiologist who received his medical degree from Hahnemann University.

1 week ago | inquirer.com | Harold Brubaker

The Malvern location of Fujirebio Diagnostics Inc.’s played key role in the clinical development of the first FDA-approved blood test that can help diagnose Alzheimer’s disease. The test, cleared May 16 for people 55 and older, is expected to help identify patients who might benefit from new drugs that have been shown to slow the type of the dementia that afflicts six million Americans.

1 week ago | inquirer.com | Harold Brubaker

Jim Wilson‘s pioneering gene therapy explorations havehelped launch eight companies focused on translating his 40 years ofresearch, mostly at the University of Pennsylvania, into treatments for rare diseases. During that time, he learned a formula that appealed toinvestors: advance the company’s science, make the company more valuableto bring in more investors, and then sell it to a big pharmaceutical company. Then a couple years ago, Big Pharma lost interest in gene therapies for rare diseases.